Danaher Co. (NYSE:DHR) Stock Holdings Increased by Fiduciary Alliance LLC

Fiduciary Alliance LLC lifted its position in Danaher Co. (NYSE:DHR) by 12.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,735 shares of the conglomerate’s stock after acquiring an additional 3,887 shares during the quarter. Danaher accounts for approximately 1.3% of Fiduciary Alliance LLC’s holdings, making the stock its 17th largest position. Fiduciary Alliance LLC’s holdings in Danaher were worth $9,935,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Tsfg LLC boosted its stake in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the period. nVerses Capital LLC bought a new position in Danaher during the 2nd quarter worth $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the second quarter worth $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher during the first quarter valued at $30,000. Finally, Richardson Financial Services Inc. acquired a new position in shares of Danaher during the fourth quarter valued at $42,000. 79.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Up 0.2 %

NYSE DHR traded up $0.50 on Monday, hitting $270.83. 335,805 shares of the company were exchanged, compared to its average volume of 2,714,967. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company’s 50 day moving average price is $270.31 and its 200-day moving average price is $259.27. The firm has a market capitalization of $200.60 billion, a P/E ratio of 45.82, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.05 EPS. The company’s revenue was down 2.9% on a year-over-year basis. Analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Ratings Changes

DHR has been the subject of a number of analyst reports. Leerink Partners boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Bank of America increased their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. TD Cowen boosted their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Stifel Nicolaus raised their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.